載入...
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis. Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ malignancies and may overcome many of the limitations of conventional leukemia therapies. We developed CART cells to target CD33...
Na minha lista:
| 發表在: | Leukemia |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4644600/ https://ncbi.nlm.nih.gov/pubmed/25721896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.52 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|